Rafferty Asset Management
AMRX icon

Rafferty Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Rafferty Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
12,966
+1,423
+12% +$19.5K ﹤0.01% 1072
2026
Q1 		$143K Sell
11,543
-7,605
-40% -$102K ﹤0.01% 1040
2025
Q4 		$241K Buy
19,148
+3,705
+24% +$42.4K ﹤0.01% 1037
2025
Q3 		$155K Sell
15,443
-1,541
-9% -$13.8K ﹤0.01% 1084
2025
Q2 		$137K Buy
16,984
+3,066
+22% +$23.1K ﹤0.01% 1063
2025
Q1 		$117K Sell
13,918
-1,745
-11% -$14.6K ﹤0.01% 1043
2024
Q4 		$124K Sell
15,663
-3,181
-17% -$26.7K ﹤0.01% 1119
2024
Q3 		$157K Buy
18,844
+1,597
+9% +$12.5K ﹤0.01% 1118
2024
Q2 		$110K Buy
17,247
+2,106
+14% +$13.4K ﹤0.01% 1159
2024
Q1 		$91.8K Buy
15,141
+3,348
+28% +$18.9K ﹤0.01% 1073
2023
Q4 		$71.6K Buy
+11,793
New +$52.5K ﹤0.01% 1068
2022
Q3 		– Sell
-33,067
Closed -$105K – 1148
2022
Q2 		$105K Buy
33,067
+8,344
+34% +$30.2K ﹤0.01% 1069
2022
Q1 		$103K Sell
24,723
-12,651
-34% -$56K ﹤0.01% 1170
2021
Q4 		$179K Sell
37,374
-575
-2% -$2.87K ﹤0.01% 1235
2021
Q3 		$203K Buy
37,949
+23,267
+158% +$117K ﹤0.01% 1192
2021
Q2 		$75K Buy
+14,682
New +$83.5K ﹤0.01% 1251
2021
Q1 		– Sell
-17,323
Closed -$79K – 1160
2020
Q4 		$79K Buy
17,323
+2,956
+21% +$13.1K ﹤0.01% 1006
2020
Q3 		$56K Buy
14,367
+2,517
+21% +$10.8K ﹤0.01% 948
2020
Q2 		$56K Buy
+11,850
New +$48.8K ﹤0.01% 968

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Rafferty Asset Management's AMRX Position: Q2 2026 in Review

Rafferty Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 12% in Q2 2026, buying an estimated $19.5K and bringing the position to 12,966 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Rafferty Asset Management first reported a position in AMRX in Q2 2020 and has held it in 19 quarters since. The position peaked at $241K in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Rafferty Asset Management held 12,966 shares of Amneal Pharmaceuticals worth $224K as of Q2 2026.
  • Rafferty Asset Management bought 1,423 Amneal Pharmaceuticals shares in Q2 2026, an estimated $19.5K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1072 holding.
  • Rafferty Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • Rafferty Asset Management's Amneal Pharmaceuticals position peaked at $241K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.